Abstract:Introduction: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that EGFR mutation status may define a patient subgroup with greater benefit from VEGF blockade. The mechanisms driving this potentially enhanced VEGF dependence are unknown. Methods: We analyzed the effect of EGFR inhibition on VEGF and HIF-1 alpha in NSCLC models in vitro and in vivo. We determined the efficacy of VEGF inhibition in xenografts and analyzed the impact of acquired EGFR inhibitor resistance on VEGF and HIF-1 alpha. Results: NSCLC cells with EGFR-activating mutations exhibited altered regulation of VEGF compared with EGFR wild-type cells. In EGFR-mutant cells, EGFR, not hypoxia, was the dominant regulator of HIF-1 alpha and VEGF. NSCLC tumor models bearing classical or exon 20 EGFR mutations were more sensitive to VEGF inhibition than EGFR wild-type tumors, and a combination of VEGF and EGFR inhibition delayed tumor progression. In models of acquired EGFR inhibitor resistance, whereas VEGF remained overexpressed, the hypoxia-independent expression of HIF-1 alpha was delinked from EGFR signaling, and EGFR inhibition no longer diminished HIF-1 alpha or VEGF expression. Conclusions: In EGFR-mutant NSCLC, EGFR signaling is the dominant regulator of HIF-1 alpha and VEGF in a hypoxiaindependent manner, hijacking an important cellular response regulating tumor aggressiveness. Cells with acquired EGFR inhibitor resistance retained elevated expression of HIF-1 alpha and VEGF, and the pathways were no longer EGFR-regulated. This supports VEGF targeting in EGFRmutant tumors in the EGFR inhibitor-naive and refractory settings. (C) 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

VEGF as a potential target in lung cancer

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects]

Angiogenesis Inhibitors in Small Cell Lung Cancer

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer

Anti-Angiogenics: Their Value in Lung Cancer Therapy

The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer

Angiogenesis and antiangiogenic agents in non-small cell lung cancer

Emerging angiogenesis inhibitors for non-small cell lung cancer

Clinical applications of VEGF-trap (aflibercept) in cancer treatment.

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Progression of VEGF-targeted cancer therapy

The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update

Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms